Kathy Miller, MD
Enriched profileBallvé Lantero Professor of Oncology, Department of Medicine, Division of Hematology/Oncology; Professor of Medicine; Associate Director of Clinical Research · Indiana University School of Medicine
Kathy Miller is Ballvé Lantero Professor of Oncology, Department of Medicine, Division of Hematology/Oncology; Professor of Medicine; Associate Director of Clinical Research at Indiana University School of Medicine. OpenAlex indexes 829 publications with 26,327 citations (h-index 77); ClinicalTrials.gov lists 29 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Kathy Miller, MD, is Ballvé Lantero Professor of Oncology, Department of Medicine, Division of Hematology/Oncology at Indiana University School of Medicine. The public record shows 829 publications with 26,327 citations (h-index 77), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology. It also documents an investigator role on 29 registered clinical trials, industry payments reported by 8 companies, 6 NIH-funded awards (2000–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Breast Cancer Treatment Studies
- 29 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 261.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 29 registered studies on ClinicalTrials.gov. The most recent:
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Sponsor: Alliance for Clinical Trials in Oncology
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
- SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Sponsor: Kathy Miller
Industry payments
Updated 18 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments
- AstraZeneca UK LimitedProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20243 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.4%Aromatase Inhibitor46.4%Anastrozole85%Exemestane9%Letrozole6%Part D≥134 patientsKinase inhibitor12.4%Ibrance56%Kisqali31%Verzenio13%Part D<11 patients+ 1 more class in this area
Nervous system
21.8%Opioid Agonist13.3%Oxycodone Hcl32%Tramadol Hcl22%Oxycodone-Acetaminophen21%Morphine Sulfate Er17%Morphine Sulfate9%Part D<11 patientsPhenothiazine2%Prochlorperazine Maleate100%Part D≥11 patients+ 5 more classes in this area
Respiratory
3.5%Opioid Agonist3.5%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
6 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:
- Building upon a tradition of excellence. The NCTN at IUSCCC
Indiana University Indianapolis
FY2026$366,921UG1CA308564 - The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability
Indiana University Indianapolis
FY2026$297,704U01CA278865 - The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability
Indiana University Indianapolis
FY2025$355,651U01CA278865
Congress activity
Updated 18 Oct 2026
203 congress contributions (2004–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 6287: Ancestry-enriched ACKR1 germline variant and its functional impact on normal and breast cancer biology.
AACR Annual Meeting
AACR2026Co-author - Abstract 7293: The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Co-Design Study Developing an Early Prototype Intervention to Support Oral Anticancer Medication Use in Breast Cancer.
Patient preference and adherence
Article2026
Most-cited works
by citation count (OpenAlex)- 01Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerArticle3,081 citations2007
- 02
- 03
- 04
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
medicine.iu.edu/faculty/4849/miller-kathy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.iu.edu ↗ - Doximity
doximity.com/pub/kathy-miller-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
cancer.iu.edu/about/members/bio/3008
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.iu.edu ↗ - Other
breastcancer.org/bio/kathy-d-miller
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.iu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.iu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.iu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.iu.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.iu.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.iu.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.iu.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.iu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.iu.edu ↗
- Medical Advisory Board Member
Living Beyond Breast Cancer (LBBC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lbbc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.iu.edu ↗
Secondary affiliations
appointments beyond the home institution- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Full Member, Experimental and Developmental Therapeutics Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.iu.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.iu.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Naga Chalasani, MD
Indiana University School of Medicine
Douglas Zipes, MD
Indiana University School of Medicine
Linda Dimeglio, MD
Indiana University School of Medicine
Patrick Loehrer, MD
Indiana University School of Medicine
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope